ClinicalTrials.Veeva

Menu

A Comparison of Crystalloid Alone Versus Crystalloid Plus Colloid in Shock Resuscitation

M

Mahidol University

Status

Unknown

Conditions

Hypotension and Shock

Treatments

Drug: Colloid solution resuscitation
Drug: Isotonic crystalloid solution resuscitation

Study type

Interventional

Funder types

Other

Identifiers

NCT02782819
Si685/2014

Details and patient eligibility

About

Fluid resuscitation is the most effective treatment of shock. Isotonic crystalloid solution is the current recommended initial fluid resuscitation. However, this kind of fluid has high volume of distribution and may require large volume administration before achieve therapeutic goal of shock reversal. There are rising concern about the delay in shock reversal and adverse consequences of large amount volume of fluid therapy. Colloid fluid have been used as the alternate fluid resuscitation, aiming to limit the volume of fluid resuscitation and promote shock reversal. Whether colloid infusion can improve shock reversal rate and decrease complication associated with fluid resuscitation, had inconclusive information.

Full description

Fluid resuscitation is the most effective treatment of shock. Isotonic crystalloid solution is the current recommended initial fluid resuscitation. However, this kind of fluid has high volume of distribution and may require large volume administration before achieve therapeutic goal of shock reversal. There are rising concern about the delay in shock reversal and adverse consequences of large amount volume of fluid therapy. Colloid fluid have been used as the alternate fluid resuscitation, aiming to limit the volume of fluid resuscitation and promote shock reversal. Data from a recent randomized controlled study showed the improve long term survival among shock patients whose resuscitated with colloid solution. There were evidence about the increase incidence of acute kidney injury among critically ill patients who received hydroxyethyl starch, a previously worldwide used colloid solution. For septic shock, the leading cause of shock in current situation, resuscitation with albumin may associated with better outcome, while increasing mortality had been reported among the patient who received hydroxyethyl starch. Whether colloid infusion can improve shock reversal rate and decrease complication associated with fluid resuscitation, had inconclusive information.

Enrollment

320 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age at least 18 years old
  • New onset of shock within 24 hours
  • Mean arterial blood pressure less than 65 mmHg or systolic blood pressure less than 60% of patient's baseline blood pressure
  • Evidence of poor tissue perfusion including: urine output less than 0.5 mL/kg/hr, lactate more than 2 mmol/L, alteration of consciousness without other explanation
  • Evidence of fluid inadequacy (CVP < 12 mmHg, Pulmonary capillary wedge pressure < 18 mmHg) or evidence of fluid responsive (IVC diameter variation > 15%, pulse pressure variation > 15%, positive fluid challenge test)

Exclusion criteria

  • Prolong shock more than 24 hours
  • Received colloid solution more than 1,000 mL in previous 72 hours
  • Do not resuscitation documented patient
  • Contraindication for fluid therapy including: suspected cardiogenic shock, evidence of pulmonary edema, history of anaphylaxis after fluid therapy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

320 participants in 2 patient groups, including a placebo group

Crystalloid
Placebo Comparator group
Description:
Isotonic crystalloid solution resuscitation
Treatment:
Drug: Isotonic crystalloid solution resuscitation
Crystalloid plus Colloid
Active Comparator group
Description:
Colloid solution resuscitation
Treatment:
Drug: Isotonic crystalloid solution resuscitation
Drug: Colloid solution resuscitation

Trial contacts and locations

1

Loading...

Central trial contact

Prapan Laophannarai, MD.; Surat Tongyoo, MD.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems